ClinicalTrials.Veeva

Menu
S

Skin Care Research | Hollywood, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ritlecitinib
Amlitelimab
CTP-543
PF-06651600
Lebrikizumab
Ixekizumab
Difamilast
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB
Etrasimod
Baricitinib

Parent organization

This site is a part of Skin Care Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 19 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ix...

Enrolling
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Active, not recruiting
Vitiligo
Device: RECELL® Autologous Cell Harvesting Device

The goal of this clinical trial is to test the safety of intralesional injections of triamcinolone self-administered into acne lesions via an injecti...

Enrolling
Acne Vulgaris
Device: Triamcinolone delivered via injection assistance device

Trial sponsors

Lilly logo
Pfizer logo
A
Concert Pharmaceuticals logo
Sanofi logo
A
Acrotech Biopharma logo
A
A
Vyne Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems